Auris Medical net loss improves in Q3

Nov. 15, 2018 7:15 AM ETAltamira Therapeutics Ltd. (CYTO)By: Mamta Mayani, SA News Editor
  • Auris Medical (EARS) Q3 results (CHF): Revenues: 0; R&D Expense: 1.7M (-59.5%); SG&A: 1.2M (-7.7%); Net Income: (3M) (+50.0%); Loss Per Share: (0.14) (+89.7%); Quick Assets: 5.3M (-64.7%).
  • Previously: Auris Medical reports Q3 results (Nov. 15)

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.